Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6–12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting

201641 citationsJournal Articlehybrid Open Access

Authors

Ann Childress · Center for Psychiatry and Behavioral Medicine

Carolyn R. Sikes · Neoleukin Therapeutics (United States)

Abstract

MPH XR-ODT was effective and well tolerated for the treatment of children with ADHD in a laboratory classroom setting. Clinical Trial Registry: NCT01835548 ( ClinicalTrials.gov ).

Topics & Keywords

Attention Deficit Hyperactivity Disorder Autism Spectrum Disorder Research Child and Adolescent Psychosocial and Emotional Development

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Child and Adolescent Psychopharmacology

Volume 27, Issue 1, pp. 66-74

DOI: 10.1089/cap.2016.0002

Field-Weighted Citation Impact: 5.38